204 related articles for article (PubMed ID: 37719651)
1. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
[TBL] [Abstract][Full Text] [Related]
2. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
3. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
[TBL] [Abstract][Full Text] [Related]
4. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
8. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
[TBL] [Abstract][Full Text] [Related]
11. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
[TBL] [Abstract][Full Text] [Related]
12. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
13. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients.
Su P; Yang CX; Wang XG
BMC Infect Dis; 2024 Jan; 24(1):44. PubMed ID: 38172735
[TBL] [Abstract][Full Text] [Related]
14. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
Diagn Microbiol Infect Dis; 2024 May; 109(4):116353. PubMed ID: 38776665
[TBL] [Abstract][Full Text] [Related]
16. Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications.
Dormuth CR; Kim JD; Fisher A; Piszczek J; Kuo IF
JAMA Netw Open; 2023 Oct; 6(10):e2336678. PubMed ID: 37782496
[TBL] [Abstract][Full Text] [Related]
17. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
[TBL] [Abstract][Full Text] [Related]
18. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients.
Haddad AJ; Hachem RY; Moussa M; Jiang Y; Dagher HR; Chaftari P; Chaftari AM; Raad II
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473412
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer.
Li F; Zheng K; Qi X; Cui K; Yang J; Hao Z
J Cancer; 2024; 15(8):2442-2447. PubMed ID: 38495484
[No Abstract] [Full Text] [Related]
20. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
